← Back to Search

Long-Acting Bronchodilator

Revefenacin (YUPELRI) & Formoterol (Perforomist) for Chronic Obstructive Pulmonary Disease

Q: How does Revefenacin (YUPELRI) & Formoterol (Perforomist) impact patient safety?

<p>The safety of Revefenacin (YUPELRI) &#x26; Formoterol (Perforomist), which is approved at the Phase 4 stage, has been rated a 3 on our team's 1-3 scale.</p>

Phase 4

Recruiting

Research Sponsored by University of Tennessee Graduate School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from day 3 borg dyspnea score at day 7

Awards & highlights

Study Summary

This trialtests a new treatment for those hospitalized due to COPD to see if it is safe, effective, and feasible.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from day 3 borg dyspnea score at day 7

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from day 3 borg dyspnea score at day 7

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from day 3 borg dyspnea score at day 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Difference in Borg Dyspnea Scale scores between groups

Bronchodilator Agents

Therapeutic procedure

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)Experimental Treatment1 Intervention

Revefenacin 175 μg once per day and Formoterol 20 μg twice per day via jet nebulizer for 7 days or until discharge if prior to day 7.

Group II: Group 2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin) as Standard of CareActive Control1 Intervention

Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mylan Pharmaceuticals IncIndustry Sponsor

163 Previous Clinical Trials

11,244 Total Patients Enrolled

University of Tennessee Graduate School of MedicineLead Sponsor

12 Previous Clinical Trials

1,064 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Revefenacin (YUPELRI) & Formoterol (Perforomist) impact patient safety?

"The safety of Revefenacin (YUPELRI) & Formoterol (Perforomist), which is approved at the Phase 4 stage, has been rated a 3 on our team's 1-3 scale."

Answered by AI

What is the maximum acceptance threshold for this clinical research program?

"Affirmative. The information on clinicaltrials.gov suggests that recruitment for this medical research is ongoing. This trial was first posted in December 9th 2020 and last updated November 13th 2022, with 60 participants sought from 1 site."

Answered by AI

Are there still vacancies available in this research protocol?

"According to the clinicaltrials.gov listing, this experiment is currently in search of participants. The trial was first advertised on December 9th 2020 and updated for the last time on November 13th 2022."

Answered by AI

What are Revefenacin (YUPELRI) & Formoterol (Perforomist) prescribed to alleviate?

"Revefenacin (YUPELRI) and Formoterol (Perforomist) are effective treatments for nasal obstruction brought on by the common cold, chronic bronchitis, or COPD."

Answered by AI

Are there any previous studies that have explored the efficacy of Revefenacin (YUPELRI) and Formoterol (Perforomist)?

"Currently, 34 trials are being conducted to study the efficacy of Revefenacin (YUPELRI) & Formoterol (Perforomist). Of those, 8 studies have reached Phase 3. While these research projects primarily take place in Ann Arbor, Michigan, there is a network of 1178 clinical trial sites that administer this treatment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Rajiv Dhand, MD 2020. "Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04655170.